Developing Immune Profiling Solutions
and
T Cell Diagnostics
Developing a Novel Portfolio of FluoroSpot T Cell Diagnostics for Indications Associated with Chronic Inflammation and T Cell Exhaustion
Vaccine Efficacy Testing
At Virax Biolabs, we’re more than just a service provider – as your dedicated partner, we are committed to accelerating the path to more effective vaccines to create lasting, impactful change in global health.
Research Tools to Investigate T Cell Immunity
ViraxImmune™ Products
Peptide Pools
Pathogen-specific linear peptides containing immunodominant epitopes, designed for efficient T cell stimulation.
ELISpot/FluoroSpot Kits
Pre-coated plates and reagents to analyse the immune response at cellular level. Multiple cytokines available.
Antibodies
High-affinity antibodies for the detection of cytokines and other biomarker in ELISA, Flow cytometry and ELISpot assays.
T Cell Testing
ELISpot assays are one of the most sensitive and specific techniques available for monitoring T cell responses permitting the ex vivo identification of cells actively secreting signaling proteins or antibodies. In addition the assay is relatively fast, highly efficient and the limit of detection achieved 1 in 100,000 cells.
Diagnosis of Viral Diseases
Immune Profiling is the detailed study and characterization of both the innate and adaptive immune responses to provide crucial insights into disease mechanisms and aiding in the development of novel therapeutic strategies. Our ViraxImmune™ IVD platform is not restricted to a single disease or condition.
Find out more about our company activites
Latest News and Media
Chronic Illness and The Immune System: Could ViraxImmune™ Offer a Critical Diagnostic Breakthrough?
A recent Wall Street Journal commentary by Yale immunologist Akiko Iwasaki and cardiologist Harlan Krumholz highlights how immune dysfunction following infection may drive a spectrum of chronic diseases—including long COVID,
Nigel McCracken, Virax COO, Discusses the New Frontier in Immune Diagnostics with The Scientist in This Innovation Spotlight.
Virax COO, Nigel McCracken, Exaplains the Latest PAIS IVD Technolgy in His Latest PharmExec.com Interview.
In His Latest PharmExec.com Interview, Virax COO Nigel McCracken Shares New Insights Into the Link Between T Cell Exhaustion and Inflammation in Long-COVID.
Virax COO, Nigel McCracken, Discusses New Data on T Cell Exhaustion in Post-Acute Infection Syndromes with PharmExec.com in Latest Article.
Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes
Sign up for more information about our products and company updates